Senior
Leadership
Team
Andrew Obenshain
Chief Executive Officer
Mr. Obenshain brings more than 20 years of global leadership in drug development, regulatory strategy, and commercialization across the United States, Europe, and international markets. He was previously the CEO of bluebird bio, recently renamed Genetix Biotherapeutics, where he led the company’s transformation into a global commercial-stage gene therapy enterprise, successfully securing multiple regulatory approvals across major geographies. Prior to bluebird, Andrew held senior leadership roles at Shire and Genzyme/Sanofi in France, with a focus on rare diseases and specialty therapeutics. He holds a B.A. in Genetics, Cell & Developmental Biology from Dartmouth College and an M.B.A. from Northwestern University’s Kellogg School of Management.
Jean Volatier
Chief Financial Officer
Jean has served as our Chief Financial Officer since August 2012. Previously, Mr. Volatier was a senior consultant for I Care Environnement, a consulting company, from January 2011 to October 2011, he also served as the interim Chief Financial Officer of the NAOS Group, a skin care company, from April 2010 to November 2010, as the Chief Financial Officer of the Soufflet Group, an agro-industry company, from 2006 to 2008, as the Financial Director — International Operations of Laboratories Fournier, from 1999 to 2006 and finally, as the Head of Controlling for URGO Soins & Santé Laboratories, a pharmaceutical company, from 1996 to 1999. Mr. Volatier began his career at PriceWaterhouseCoopers, where he worked from 1989 to 1996. He holds a master’s degree in Management from Paris IX Dauphiné University, PSL University, an executive specialized master’s degree in Corporate Social Responsibility from MINES-ParisTech, PSL University, and the “Diplôme d’Études Supérieures Comptables et Financières”.
Jason Campagna, MD, PhD,
President of R&D and Chief Medical Officer
Jason brings over two decades of leadership experience in early- and late-stage clinical development across several leading biopharmaceutical companies. Most recently, he served as CMO at Q32 Bio, overseeing clinical strategy and development. Prior to that, Jason held multiple leadership roles at Intercept Pharmaceuticals, including as Head of its Global MASH Program that resulted in the submission of the first-ever NDA for a therapeutic targeting of MASH to the FDA, and ultimately served as CMO with global responsibility for the PBC franchise, the Global MASH program, and broader pipeline strategy. Before joining Intercept in 2016, Jason held positions of increasing responsibility at The Medicines Company, including as Senior Vice President and Health Science Lead for Surgery and Perioperative Care.
Martine Zimmermann, PharmD
EVP, Regulatory Affairs and Quality Assurance
Martine brings over 25 years of combined experience in R&D and global regulatory strategy. Most recently, she served as Senior Vice President, Head of Regulatory Affairs at Ipsen, where she successfully led the team that secured regulatory approvals for two liver disease therapies, including a dual PPARα/δ agonist for the treatment of primary biliary cholangitis. Prior to Ipsen, Martine was Senior Vice President and Head of Global Regulatory Affairs & Quality at Alexion Pharmaceuticals (now AstraZeneca Rare Disease). In this role, she was instrumental in advancing the registration of multiple orphan medicinal products worldwide and actively contributed to shaping the regulatory landscape for rare disease therapies. Earlier in her career, Martine held R&D and regulatory leadership positions at Aventis (now Sanofi), Servier, and H. Lundbeck A/S.
A recognized advocate for diversity, equity, inclusion, and belonging, Martine was honored as a Luminary by the Healthcare Businesswomen’s Association in 2020. She also served as an executive sponsor for Alexion’s flagship Women in Leadership (WIL) employee resource group. Martine earned her Doctor of Pharmacy (PharmD) from the University Louis Pasteur in Strasbourg, France.
Alice Roudot-Ketelers, PharmD
Chief Operating Officier
Alice brings over 20 year of experience in clinical and pharmaceutical development. Prior to joining Inventiva, Alice was in charge of all drug development programs and oversaw cross-functional teams in Chemistry, Manufacturing and Controls (CMC), non-clinical and clinical development up to Phase 3 at one of the major biotech companies in the NASH field.
Alice holds a Master of Science in industrial pharmacy from the Institute of Industrial Pharmacy – University of Lyon and a Doctorat of Pharmacy from the University of Lille II.
Pascaline Clerc, PhD
EVP, Strategy and Corporate Affairs
Pascaline serves as our EVP of Strategy & Corporate Affairs. Pascaline boasts a rich and diverse background that seamlessly integrates scientific expertise with a profound understanding of policy, advocacy, and communications. With a 20+ year career that spans academia, government, non-profit, and biotech sectors, Pascaline has developed a specialty in NASH/MASH and brings a unique perspective to the intersection of science and public engagement.
Prior to joining Inventiva, Pascaline lead the global strategy for public policy and patient advocacy engagement for a leading biotech in NASH/MASH.
Pascaline holds a Master of Sciences in Biochemistry, Cellular & Molecular Biology, and a PhD in Cellular Biology from the prestigious University Grenoble-Alpes in France. Pascaline was awarded a Science & Technology Policy fellowship by the American Association for the Advancement of Science (AAAS).
Consult Pascaline’s profileNathalie Harroy
Head of Human Resources
Nathalie has held the position of Head of Human Resources since the creation of Inventiva in 2012. She has developed her expertise in human resources (HR) in the field of research and development within the pharmaceutical industry for thirty years. She began her career at Urgo Laboratories, before joining Fournier Laboratories in 1994 where she devoted herself to R&D. In 2001, within the newly created Scientific Affairs Division, she actively participated in the establishment of a new research organization adapted to the Group’s challenges by equipping the organization with the required Human Resources support and skills. After the acquisition of Fournier Laboratories by Solvay and then Abbott, she was involved in cross-cutting HR projects in France for Solvay Pharmaceuticals and then for Abbott Pharmaceuticals.
Eric Duranson, LLM
General Counsel
Eric is a corporate lawyer with over 20 years of experience in the life sciences industry (in vitro diagnostics, human vaccine, medical devices) having worked companies such as Thermo Fisher Scientific, Sanofi Pasteur and bioMérieux, throughout all product development stages, from research and development to marketing. He brings to Inventiva his experience in risk prevention, contracts negotiation and drafting and dispute resolution.
Eric holds a master degree in International Business Law and a master degree in Ethics and Health Law from University Jean Moulin, Lyon III.
